(Source: CytomX Therapeutics Inc) SOUTH SAN FRANCISCO, Calif., Oct. 26, 2015 /PRNewswire/ -- CytomX Therapeutics (Nasdaq: CTMX), a biopharmaceutical company developing Probody™ therapeutics for the treatment of cancer, today announced that preclinical results from its Probody therapeutics pipeline have been accepted for presentation at the 2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. The conference will take place November 5-9 at the Hynes Convention Center in Boston. Therapeutics developed with CytomX's Probody platform are designed to be active in the tumor while sparing healthy tissue. This design is intended to avoid the toxicities that have...
↧